Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Weighted Average)
Others
Ratios

Evogene (EVGN) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Evogene (EVGN) over the last 14 years, with Q3 2025 value amounting to $3.9 million.

  • Evogene's Net Income towards Common Stockholders rose 15077.33% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.7 million, marking a year-over-year increase of 8831.28%. This contributed to the annual value of -$16.5 million for FY2024, which is 3096.44% up from last year.
  • Evogene's Net Income towards Common Stockholders amounted to $3.9 million in Q3 2025, which was up 15077.33% from -$4.5 million recorded in Q2 2025.
  • In the past 5 years, Evogene's Net Income towards Common Stockholders registered a high of $8.8 million during Q2 2022, and its lowest value of -$8.3 million during Q1 2022.
  • Its 5-year average for Net Income towards Common Stockholders is -$4.2 million, with a median of -$6.2 million in 2021.
  • Per our database at Business Quant, Evogene's Net Income towards Common Stockholders tumbled by 25900.54% in 2021 and then surged by 24204.51% in 2022.
  • Evogene's Net Income towards Common Stockholders (Quarter) stood at -$7.4 million in 2021, then skyrocketed by 59.33% to -$3.0 million in 2022, then crashed by 120.18% to -$6.6 million in 2023, then skyrocketed by 106.47% to $427000.0 in 2024, then surged by 807.26% to $3.9 million in 2025.
  • Its Net Income towards Common Stockholders stands at $3.9 million for Q3 2025, versus -$4.5 million for Q2 2025 and -$2.6 million for Q1 2025.